Adverse Events Following Immunization Among Children With Epilepsy: A Self-Controlled Case Series

Karina A Top1,2, Christiaan H Righolt3, Steven Hawken4,5,6

  • 1From the Departments of Pediatrics.

Insights

In children with epilepsy, a modest increase in seizure-related emergency visits occurred after inactivated and live vaccines. This risk is small compared to the dangers of vaccine-preventable diseases.

Area of Science:

  • Pediatrics
  • Neurology
  • Immunology

Background:

  • Fever and illness can trigger seizures in children with epilepsy.
  • Concerns exist that vaccine-induced inflammation and fever might also trigger seizures.
  • This study investigated the risk of seizures following immunization in children with epilepsy.

Purpose of the Study:

  • To estimate the risk of emergency department (ED) visits or hospitalizations for epilepsy/seizure after immunization in children younger than 7 years with epilepsy.
  • To assess the risk of all-cause ED visits or hospitalizations post-immunization in this population.

Main Methods:

  • A self-controlled case series design was used, analyzing administrative healthcare data from Ontario and Manitoba, Canada (2005-2015).
  • Children diagnosed with epilepsy before age 7 and immunized were included.
  • Age- and season-adjusted relative incidence (aRI) of ED visits/hospitalizations was calculated for specific periods post-inactivated and live immunizations compared to a control period.

Main Results:

  • The risk of epilepsy/seizure-related ED visits/hospitalizations modestly increased 0-2 days after inactivated vaccines (aRI = 1.5) and 7-10 days after live vaccines (aRI = 1.9).
  • All-cause ED visits/hospitalizations showed a combined aRI of 0.9 after inactivated vaccines and 1.3 after live vaccines during the respective risk periods.
  • These findings indicate a slight increase in seizure risk following vaccination in children with epilepsy.

Conclusions:

  • The risk of epilepsy/seizure-related ED visits/hospitalizations is modestly increased in children with epilepsy following inactivated and live vaccines.
  • This increased risk occurs during periods of peak fever and inflammation post-vaccination.
  • These risks should be weighed against the significant benefits of protection from vaccine-preventable diseases.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
729
Vaccinations01:51

Vaccinations

Overview
50.9K